ITIpek Turktas

Ipek Turktas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ipek Turktas has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Arzu Bakirtas

    Department of Pediatric Allergy, Gazi University Faculty of Medicine, Ankara, Türkiye

    4 shared publications
  • Mustafa Arga

    Department of Pediatric Allergy and Immunology, İstanbul Medeniyet University Faculty of Medicine Göztepe Prof. Dr. Süleyman Yalçın City Hospital Istanbul Turkey

    4 shared publications
  • Erdem Topal

    Faculty of Medicine, Pediatric Allergy and Immunology Department Inonu University Malatya Turkey

    3 shared publications
  • M. Sadik Demirsoy

    Department of Pediatric Emergency, Gazi University Faculty of Medicine, Ankara, Turkey

    2 shared publications
  • Arzu Bakirtas

    Department of Pediatric Allergy and Asthma, Gazi University Faculty of Medicine, Ankara, Turkey

    1 shared publication
  • Ferhat Catal

    Department of Pediatric Allergy and Asthma, Gazi University Faculty of Medicine, Ankara, Turkey

    1 shared publication

Latest Publications

  • Predictive factors to differentiate between allergic and nonallergic rhinitis in children

    by Erdem Topal, Arzu Bakirtas, Ozlem Yılmaz, Ilbilge Hacer Ertoy Karagöl, Umut Arslan, Mustafa Arga, Mehmet Sadik Demirsoy, Ipek Turktas

    Background Although symptoms and signs of allergic rhinitis (AR) and nonallergic rhinitis (NAR) are similar, treatment and follow-up are different. We aimed to find predictive factors that can be used in primary health care to differentiate AR from NAR. Methods We made a retrospective analysis of cases aged 6–18 years old who were diagnosed as having chronic rhinitis within a 1-year period. Skin-prick tests were done and severity of rhinitis symptoms was recorded on a visual analog scale in all patients. Results There were 472 cases whose medical records were complete and included in the analysis. The median age was 11 (interquartile range [IQR], 5) years. AR was diagnosed in 363 patients (76.9%) and was different from NAR with respect to: median age (p = 0.042), seasonality of the symptoms (p = 0.002), persistent symptoms (p = 0.003), moderate/severe according to visual analogue scale (VAS) score (p = 0.017), conjunctivitis (p < 0.001), parental history of AR (p = 0.026), rhinorrhea (p < 0.001), sneezing (p = 0.005), mucosal pallor (p = 0.004), and response to antihistamines (p = 0.035). All parameters with a significance of p < 0.1 between AR and NAR were included in logistic regression analysis. Seasonality, sneezing, moderate/severe rhinitis, and response to antihistamines were identified as significant independent parameters to differentiate AR from NAR. Conclusion Features of rhinitis patients with seasonality, sneezing, moderate/severe rhinitis, and response to antihistamines may help in differentiation of AR from NAR at the primary care level.


  • Management Preferences of Pediatricians in Moderate and Severe Acute Asthma

    by Mustafa Arga, Arzu Bakirtas, Ferhat Catal, Oksan Derinoz, Erdem Topal, M. Sadik Demirsoy, Ipek Turktas

    To assess and compare management preferences of physicians for moderate and severe acute asthma based on case scenarios and to determine the factors influencing their decisions. A questionnaire based on the Global Initiative on Asthma (GINA) guideline and comprising eight questions on management of acute asthma was delivered to participants of two national pediatric congresses. Management of moderate and severe acute asthma cases was evaluated by two clinical case scenarios for estimation of acute attack severity, initial treatment, treatment after 1h, and discharge recommendations. A uniform answer box comprising the possible choices was provided just below the questions, and respondents were requested to tick the answers they thought was appropriate. Four-hundred and eighteen questionnaires were analyzed. All questions regarding moderate and severe acute asthma case scenarios were answered accurately by 15.8% and 17.0% of physicians, respectively. The initial treatment of moderate and severe cases was known by 100.0% and 78.2% of physicians, respectively. Knowledge of the appropriate plan for treatment after 1h was low both for moderate (45.0%) and severe attacks (35.4%). Discharge recommendations were adequate in 32.5% and 70.8% of physicians for moderate and severe attacks, respectively. Multiple logistic regression analysis revealed that working at a hospital with a continuing medical education program was the only significant predictor of a correct response to all questions regarding severe attacks (p = .04; 95%CI, 1.02-3.21). No predictors were found for information on moderate attacks. Pediatricians have difficulty in planning treatment after 1 hour both for moderate and severe asthma attacks. Postgraduate education programs that target physicians in hospitals without continuing medical education facilities may improve guideline adherence.


  • Effect of epinephrine autoinjector design on unintentional injection injury

    by Mustafa Arga, Arzu Bakirtas, Erdem Topal, Ozlem Yilmaz, Ilbilge Hacer Ertoy Karagol, M. Sadik Demirsoy, Ipek Turktas

    Epinephrine is an essential medication for the treatment of anaphylaxis. Factors associated with autoinjector design may have a role in its correct use. We compared a new and old epinephrine autoinjector with respect to correct autoinjector use. We invited all interns of the 2011‐2012 training period in our medical school. The participants were randomly assigned into two groups. After all participants were given a three-step written and visual instruction sheet about epinephrine autoinjector use, they were asked to show its use either with the old or the new epinephrine autoinjector trainer. The old and new trainers, which were exactly identical to the original epinephrine autoinjectors except for the medication and needle, were used. The performance of each participant was assessed with a standardized scoring system. Among 220 invited interns, 180 (81.8%) were enrolled. The number of participants correctly showing the use of epinephrine autoinjectors and the mean total score did not differ significantly between the two groups (p = 0.639 and p = 0.233, respectively). Significantly fewer participants had unintentional injections in the new compared with the old epinephrine autoinjector group (p < 0.001). When all assessment steps are considered, only the rate of placing a wrong tip into the outer thigh was significantly lower in the new compared with the old epinephrine autoinjector group (p < 0.05). The new epinephrine autoinjector is more effective in unintentional injection injuries than the old one; however, it still does not fulfill the criteria of an ideal epinephrine autoinjector.


  • Open Access

    First Experience with Omalizumab in a Child with Severe Persistent Asthma in Turkey: Case Report

    by Mustafa Arga, Arzu Bakirtaş, İpek Türktaş, M. Sadık DEMİRSOY

    Human monoclonal anti-IgE antibody (omalizumab) is recently recommended at the fifth step of international asthma guidelines for the treatment of patients older than 12 years of age who have severe persistent allergic asthma uncontrolled despite treatment with high-dose inhaled corticosteroid (>800 µgr/day) in combination with a long-acting ?2-agonist and oral leukotriene receptor antagonist and have serum total Ig E between 30-700 IU/ml. We started omalizumab as add-on treatment to a severe persistent asthmatic case who had two severe asthma attacks in the last three-month period, one of which was complicated with pneumomediastinium. This is the first experience with omalizumab in a child with severe asthma reported from our country. The first seven-month of omalizumab treatment resulted in significant improvements in quality of life and pulmonary functions as well as reductions in inhaled corticosteroid dose and daily symptom scores.


  • Diagnostic accuracy of skin‐prick testing in young children with asthma

    by Ipek Turktas, Koray Harmanci, Arzu Bakirtas